<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Winhusen TJ</submitter><funding>National Institute on Drug Abuse Clinical Trials Network</funding><funding>Eunice Kennedy Shriver National Institute of Child Health and Human Development</funding><funding>NIDA NIH HHS</funding><funding>University of Cincinnati</funding><funding>National Institutes of Health</funding><funding>National Institute of Child Health and Human Development</funding><pagination>112795</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12444429</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>275</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Overdose is a leading cause of pregnancy-associated mortality in the US. Our personally-tailored opioid-overdose (OOD) and medication for opioid use disorder (MOUD) education intervention has been shown to significantly improve MOUD/OOD knowledge in out-of-treatment persons using illicit opioids. We evaluated the ability of the intervention modified for peripartum (pregnant or within one year postpartum) individuals, the personally-tailored OOD and MOUD education (TOME) intervention, to increase MOUD (primary) and OOD (key secondary) knowledge.&lt;h4>Methods&lt;/h4>A six-site, two-arm, open-label, trial with 131 peripartum individuals receiving MOUD (methadone or buprenorphine) randomized to TOME, a 15-minute, computer-facilitated, individually-tailored intervention, or Contro</pubmed_abstract><journal>Drug and alcohol dependence</journal><pubmed_title>Personally-tailored opioid-overdose and medication for opioid use disorder (MOUD) education (TOME) significantly increases MOUD and overdose knowledge in peripartum individuals: Results from a randomized controlled pilot trial.</pubmed_title><pmcid>PMC12444429</pmcid><funding_grant_id>UG1DA013720</funding_grant_id><funding_grant_id>U10 DA013732</funding_grant_id><funding_grant_id>UG1DA049436</funding_grant_id><funding_grant_id>UG1 DA013727</funding_grant_id><funding_grant_id>UG1 DA049444</funding_grant_id><funding_grant_id>UG1DA049444</funding_grant_id><funding_grant_id>UG1DA013727</funding_grant_id><funding_grant_id>UG1 DA049436</funding_grant_id><funding_grant_id>UG1 DA013732</funding_grant_id><funding_grant_id>UG1DA013732</funding_grant_id><funding_grant_id>UG1 DA013720</funding_grant_id><pubmed_authors>Winhusen TJ</pubmed_authors><pubmed_authors>Rosa C</pubmed_authors><pubmed_authors>Dilawar M</pubmed_authors><pubmed_authors>Kropp F</pubmed_authors><pubmed_authors>Cochran G</pubmed_authors><pubmed_authors>Krans EE</pubmed_authors><pubmed_authors>Lofwall MR</pubmed_authors><pubmed_authors>Davies TH</pubmed_authors><pubmed_authors>Smid MC</pubmed_authors><pubmed_authors>Young JL</pubmed_authors><pubmed_authors>Lewis D</pubmed_authors><pubmed_authors>Hodgkins C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Personally-tailored opioid-overdose and medication for opioid use disorder (MOUD) education (TOME) significantly increases MOUD and overdose knowledge in peripartum individuals: Results from a randomized controlled pilot trial.</name><description>&lt;h4>Background&lt;/h4>Overdose is a leading cause of pregnancy-associated mortality in the US. Our personally-tailored opioid-overdose (OOD) and medication for opioid use disorder (MOUD) education intervention has been shown to significantly improve MOUD/OOD knowledge in out-of-treatment persons using illicit opioids. We evaluated the ability of the intervention modified for peripartum (pregnant or within one year postpartum) individuals, the personally-tailored OOD and MOUD education (TOME) intervention, to increase MOUD (primary) and OOD (key secondary) knowledge.&lt;h4>Methods&lt;/h4>A six-site, two-arm, open-label, trial with 131 peripartum individuals receiving MOUD (methadone or buprenorphine) randomized to TOME, a 15-minute, computer-facilitated, individually-tailored intervention, or Contro</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Oct</publication><modification>2026-06-03T15:32:14.42Z</modification><creation>2026-06-01T03:06:08.841Z</creation></dates><accession>S-EPMC12444429</accession><cross_references><pubmed>40700987</pubmed><doi>10.1016/j.drugalcdep.2025.112795</doi></cross_references></HashMap>